

Desquamative gingivitis: A sign of mucocutaneous disorders – a review

NA Robinson,* D Wray†

Abstract

Desquamative gingivitis is a clinical term to describe red, painful, glazed and friable gingivae which may be a manifestation of some mucocutaneous conditions such as lichen planus or the vesiculobullous disorders. It is important to be aware of this rare clinical entity so as to distinguish desquamative gingivitis from plaque induced gingivitis which is an extremely common condition, easily recognized and treated daily by the dental practitioner. This article gives an overview of desquamative gingivitis, its presentation, the possible causes, diagnosis and treatment. Early recognition of these lesions may prevent delayed diagnosis and inappropriate treatment of potentially serious dermatological diseases.

Key words: Gingivitis, lichen planus, pemphigus, pemphigoid, immunofluorescence.

(Accepted for publication 24 April 2003.)

INTRODUCTION

The term desquamative gingivitis (DG) is used in this paper as a clinical description of the gingiva which may manifest as a result of various underlying conditions to be discussed below. It is characterized by fiery red, glazed, atrophic or eroded looking gingiva. There is loss of stippling and the gingiva may desquamate easily with minimal trauma (Fig 1, 2). As opposed to plaque induced gingivitis, DG is more common in middle-aged to elderly females, is painful, affects the buccal/labial gingiva predominantly, frequently spares the marginal gingiva but can involve the whole thickness of the attached gingiva and its clinical appearance is not significantly altered by traditional oral hygiene measures or conventional periodontal therapy alone (Table 1).^{1,2}

The majority of cases of DG are now known to be due to mucocutaneous conditions, in particular lichen

planus, pemphigoid and pemphigus.³⁻⁶ Other causes include allergic reactions to toothpastes/mouth rinses (plasma cell gingivitis),⁷⁻⁹ Crohn's disease,¹⁰ psoriasis,¹¹ linear IgA disease¹² and chronic ulcerative stomatitis.¹³ Desquamative gingivitis can be mistaken for plaque induced gingivitis and this can lead to delayed diagnosis and inappropriate treatment of serious dermatological diseases such as pemphigoid or pemphigus.¹⁴⁻¹⁷ The common mucocutaneous conditions which may manifest as DG are outlined below.

Gingival lichen planus

Desquamative gingivitis as a presenting feature is most commonly noticed in oral lichen planus (OLP).^{1,3,6} Lichen planus is a relatively common immunologically mediated mucocutaneous disease of unknown aetiology. It is more common in middle-aged to elderly females. Several forms of OLP are described intra-orally; reticular, papular, plaque-like, atrophic, bullous and erosive forms. The most common site of involvement is the buccal mucosa followed by the tongue and the gingiva. The characteristic features of OLP are its chronicity, symmetrical appearance and multi-site involvement.¹⁸

The gingiva may be the only site of involvement in about 10 per cent of cases. The atrophic form of OLP presents often on the gingiva giving the classical appearance of DG. The whole thickness of the attached gingiva up to the mucogingival junction may be affected (Fig 3). The gingival tissues appear erythematous with occasional areas of erosions and possibly white striae at the periphery. Patients may complain of persistent soreness of the gums which is made worse by spicy foods or when carrying out daily oral hygiene procedures. The latter may become restricted to the point that plaque induced gingivitis and periodontitis sets in, confusing the clinical picture. However, it is important to note that the immunological reaction occurring in lichen planus does not result in clinical attachment loss and periodontitis.¹⁹⁻²¹

Diagnosis of OLP can be difficult if the gingiva is the only site of involvement. Careful examination of the erythematous gingiva may reveal faint keratotic lines. The rest of the oral mucosa should be examined

*Adjunct Fellow, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, National University of Singapore.

†Professor of Oral Medicine and Dean, Glasgow Dental School, Faculty of Medicine, The University of Glasgow.



Fig 1. Fiery, red gingiva of desquamative gingivitis. The clinical features are non-specific. This patient has mucous membrane pemphigoid.



Fig 3. Gingival lichen planus showing no pathognomonic gingival features but associated with buccal reticular lichen planus.



Fig 2. Desquamative gingivitis. Note that the patient has relatively good oral hygiene but the attached gingiva have lost their keratinization making them more susceptible to desquamation with trauma.

carefully for evidence of classical lichenoid lesions. The patients should be questioned and examined for the presence of any cutaneous lesions. The most common cutaneous site involved in lichen planus is the flexural surface of the wrist, presenting as intensely pruritic, purple, polyglonal papules. Other sites that can be affected are the nails, scalp, oesophagus and the genital mucosa. In recent years, there have been reports of concomitant involvement of the genital mucosa and the gingiva, especially in females. This association of lichen planus of the vulva, vagina and the gingiva (presenting as classical DG) has been termed the vulvovaginal-gingival syndrome.^{22,23}

An incisional biopsy is necessary to confirm the diagnosis of OLP. The biopsy should be taken well away from the marginal gingiva as plaque-induced

gingival inflammation may complicate the histological picture. The specimen taken should have intact epithelium as well. The tissue specimen should be transected; one piece fixed in formalin and examined under light microscopy and the other transported fresh to an appropriate laboratory to be snap-frozen immediately in liquid nitrogen. The latter specimen is then processed for immunofluorescent staining. These tests serve to detect the presence of autoantibodies and other inflammatory proteins within the tissues (direct immunofluorescence). The patient's tissue is incubated with fluorescence labeled anti-sera against human antibodies, complement component 3 (C3) and fibrinogen. The specimen is then examined under ultraviolet microscopy.²⁴ In OLP deposits of fibrinogen alone are seen along the basement membrane zone. As stated earlier the atrophic form of lichen planus affects the gingiva and the typical light microscopic features of gingival lichen planus are:²⁵ severe thinning and flattening of the epithelium; basal cell liquefaction degeneration; and a subepithelial, dense, band-like infiltrate of lymphocytes (with a sharply demarcated lower border) hugging the epithelio-mesenchymal junction.

Treatment of gingival lichen planus is as for the other forms of intra-oral lichen planus.^{21,26} Effective but atraumatic oral hygiene needs to be instituted as well as professional scaling and root planning.^{2,27} Topical corticosteroids are the mainstay of treatment for lichen planus and should be applied directly onto the affected gingiva. Vacuum formed custom trays or gingival veneers can be constructed to achieve this. Patients are instructed to apply the topical steroids on the fitting surface of the splints which can be worn overnight. Additionally, the splints serve to protect the friable gingiva.^{28,29} For patchy involvement of the gingiva, localized delivery of corticosteroids can be achieved with a topical beclomethasone spray. Systemic tetracycline³⁰ and recently topical cyclosporin (mouth wash),³¹ has been used for DG as well. For recalcitrant OLP, topical tacrolimus has recently been tried with promising results.³²

Table 1. Clinical features of desquamative gingivitis

Fiery, red, friable gingiva
Painful, desquamates easily
Buccal aspect of anterior attached gingiva affected
Marginal gingiva spared
Not significantly improved by oral hygiene measures alone

Table 2. Immune-mediated blistering diseases

<i>Intra-epithelial</i>
Pemphigus
<i>Subepithelial</i>
Pemphigoid
Linear IgA disease
Dermatitis herpetiformis
Epidermolysis bullosa
Erythema multiforme

Immune-mediated blistering diseases (vesiculobullous disorders)

These have traditionally been divided into intra-epithelial and subepithelial disorders (Table 2).³³ The most common presentation of mucous membrane pemphigoid intra-orally is DG. The other bullous diseases of which DG is the presenting oral manifestation include pemphigus, linear IgA disease, dermatitis herpetiformis and occasionally erythema multiforme.³ A detailed review of the above vesiculobullous disorders is beyond the scope of this article. The interested practitioner is referred to recent excellent reviews, cited below.³⁴⁻³⁷

Mucous membrane pemphigoid

Mucous membrane pemphigoid (MMP) as defined in a recent consensus statement,³⁸ is a 'group of putative autoimmune, chronic inflammatory, subepithelial blistering diseases predominantly affecting mucous membranes, with or without clinically observable scarring'. Antibodies are produced against certain target antigens found in the basement membrane, resulting in the epithelium being detached from the underlying lamina propria. In recent years detailed characterization of the various target antigens have been made and subsets of pemphigoid subsequently identified.³⁴⁻³⁶ Mucous membrane pemphigoid chiefly affects the oral cavity, larynx, oesophagus and ocular membranes but rarely the skin. Females in their sixth decade tend to be afflicted more commonly but males and patients in other age groups can be affected as well. The most common presentation intra-orally is DG. The typical appearance of DG as described earlier is seen in



Fig 4. Desquamative gingivitis in a patient with pemphigoid bulla formation. Mucous membrane pemphigoid was confirmed by immunofluorescence.



Fig 5. Ocular pemphigoid showing scarring which has led to the term cicatricial pemphigoid.

MMP. There might be areas of superficial erosions and tags of detached epithelium on the gingiva (Fig 4). Other oral mucosal sites involved are the buccal mucosa, palate, alveolar ridge and tongue. Rarely are intact bulla seen intra-orally (the traditional description of blood-filled bullae on the palate is seldom observed), the more common presentation being fibrin covered superficial erosions with irregular margins. Oral lesions tend to heal over without scarring. Unfortunately this is not so in the other mucosal sites chiefly the conjunctiva. The eyes can be affected in as high as 80 per cent of cases with 15 per cent developing permanent blindness as a result of subconjunctival scarring (Fig 5).³³ Less commonly, strictures may form in the larynx, oesophagus and genital mucosa with serious complications.³⁵⁻³⁸

The diagnosis of MMP depends on taking a careful clinical history and performing a thorough clinical examination. The gingiva can be the only site of involvement in MMP and this frequently results in delayed diagnosis as the patient is put through repeated sessions of periodontal therapy and/or prescribed various antimicrobials. The classical features of DG are usually present in the gingiva. The patient usually gives a long history of gingival soreness. Long standing superficial erosions may be present on the gingiva or on other sites and this will help in the diagnosis.³⁹

However, the definitive diagnosis depends on histological examination of the gingival tissues. A biopsy needs to be taken from an area with intact epithelium (eroded sites are uninformative). Some advocate inducing a blister by stroking the epithelium (Nikolsky's sign) and then removing the blister intact.⁴⁰ The tissue specimen should be transected as before; one piece for routine light microscopy studies and the other for immunofluorescent staining. In MMP, linear deposits of IgG and C3 are most commonly detected in the basement membrane zone. Indirect immunofluorescence involves incubating the patient's serum with normal skin. If antibodies are present in the patient's sera they will bind to the target antigens in the normal specimen and this is then detected by similarly labeled anti-human immunoglobulins. In the past,

circulating antibodies in MMP were rarely detected or were of low titers that did not correlate with disease activity.⁴¹ However, with the use of chemically separated normal human epithelium as substrate, detection rates for circulating autoantibodies in patients with MMP have reported to be between 88 to 100 per cent.⁴² Further, recent evidence suggest that serial titers of IgG as well as IgA, detected on salt-split human skin, may correlate with disease activity and severity.^{43,44}

To summarize the histological features of MMP are: subepithelial bulla formation; no acantholysis; chronic inflammatory infiltrate in the lamina propria; and linear deposition of IgG, IgA or C3 along the basement membrane.^{33,35,36,45}

Once a diagnosis of MMP is made, an ophthalmologic opinion should be sought even if patients do not complain of eye symptoms. Ocular symptoms can be mild initially and then presents as chronic conjunctivitis before more serious scarring takes place. A slit-lamp examination should be carried out by the ophthalmologist early in the disease so that appropriate therapy can be instituted. Glaucoma appears to be more common in MMP patients and this argues for an early ophthalmologic consult as well.⁴⁶

Oral lesions are typically indolent. They can usually be controlled with topical corticosteroids and if DG is present a custom made splint is used for the gingiva as in lichen planus, described earlier. The more potent topical steroids may need to be used initially until symptoms subside. Oral hygiene must be improved and regular professional cleaning should be emphasized. If other mucosal sites or the skin is involved then more potent medication such as systemic corticosteroids, azathioprine, sulphapyridine or dapsone is used.^{33,35,38,47}

Pemphigus

Pemphigus is one of the very few potentially fatal mucocutaneous diseases characterized by intra-epithelial bullous formation. It is an uncommon condition and usually affects females in their fourth to fifth decade of life. Pemphigus vulgaris is the most important subtype to occur in the mouth and it can be the initial site of presentation in 50 per cent of cases. In pemphigus vulgaris, antibodies are produced against desmosomes (adhesion proteins), in particular, desmoglein 3. The latter is one of the components of desmosomes responsible for holding the spinous cell layer of the epithelium together. The intercellular adhesion between the spinous cells is disrupted resulting in bulla formation immediately suprabasal.^{33,34,48} In pemphigus foliaceus, which predominantly affects skin, autoantibodies are produced against desmoglein 1.⁴⁹ It has been shown that a subset of patients with pemphigus vulgaris may have antibodies against desmoglein 1 as well.⁵⁰ The clinical significance of this will be explained later.

Oral pemphigus vulgaris presents as bullae that break down rapidly to leave persistent irregular ragged edged painful erosions. Any site subjected to trauma

may be involved especially the palate, tongue and buccal mucosa. Gingival involvement may manifest as DG though less commonly than pemphigoid. There is severe desquamation of the gingiva more so than other vesiculobullous diseases. Bullae on the gingiva rupture leaving painful eroded areas. Gentle pressure on the epithelium may result in its separation and normal activities such as oral hygiene procedures and having meals becomes extremely painful for the patient.^{17,51} Other sites that can be involved include the oesophagus, pharynx, larynx, nasal and genital mucosae. Although ocular lesions can occur in pemphigus, they are uncommon and tend to be transient and heal completely without scarring. Skin lesions present as flaccid fluid filled blisters on sites exposed to trauma. The blisters break to form large denuded areas of skin. In the past before the use of steroids the mortality was 30 per cent as a result of electrolyte loss and sepsis.^{33,52}

Definitive diagnosis depends on taking a biopsy specimen with an intact epithelium. This can be difficult in pemphigus as the epithelium is very friable. Again a fresh and a formalin-fixed specimen is needed. Direct immunofluorescence demonstrates deposition of IgG and C3 intercellularly in a fish-net pattern. Circulating autoantibodies can usually be detected by indirect immunofluorescence and the titers of such antibodies usually correspond to disease activity and severity.^{24,33,40,50} Specific enzyme-linked immunosorbent assays (ELISA) are now available for detecting desmoglein 3 and desmoglein 1 autoantibodies.⁵³ As stated earlier, patients with pemphigus vulgaris have autoantibodies mainly against desmoglein 3. Recent data suggest that the detection of desmoglein 1 antibodies in patients with oral pemphigus vulgaris signifies a more severe course of the disease and heralds the involvement of cutaneous sites as well.^{50,54}

Conventional histology demonstrates:⁴⁵ acantholysis; suprabasal bulla formation; free-floating acantholytic cells within the vesicle fluid (Tzanck cells); intact basal cell layer, still attached to basal lamina; and mild inflammatory infiltrate.

Early diagnosis of pemphigus vulgaris is important as it is a serious condition. Lesions present initially in the mouth. It can then rapidly spread to skin or other mucosal sites. Alternatively the mouth may be the only site of involvement for about six months to a year before the skin is involved. The key here is early diagnosis and institution of therapy before skin and other sites are involved.^{14,17,55} Referral to a dermatologist is advised.

Systemic corticosteroids are the mainstay of treatment. These are given initially in high doses orally or if the disease is severe and rapidly progressing, in the form of pulse therapy with megadoses of corticosteroids (intravenously). Once the disease is under control, the steroids can be tapered off and 'steroid-sparing' adjuncts added. These include azathioprine, cyclosporin, cyclophosphamide and

methotrexate. Other therapies include photopheresis and plasmapheresis. The progress of therapy is evaluated by clinical response as well as a falling circulating antibody titer. Desquamative gingivitis in pemphigus is treated additionally with topically steroids as described earlier. It must be appreciated that pemphigus is a systemic autoimmune disease with a potentially rapid progressive course and so topical steroids alone are insufficient to treat the condition. Treatment may need to be lifelong as stopping therapy may result in exacerbation of the disease. The mortality of pemphigus is currently around 6 per cent and is due to the effects of immunosuppressive therapy.⁵⁶⁻⁵⁸

Others

Linear IgA disease

This is a rare subepithelial vesiculobullous disease characterized by deposition of IgA autoantibodies in a linear pattern along the basement membrane zone. Oral lesions can mimic those seen in mucous membrane pemphigoid. The gingiva can exhibit a typical diffuse DG. Non-specific oral ulcerations also occur on the palate, tongue and buccal mucosa. This disease, as opposed to dermatitis herpetiformis, is not associated with a gluten sensitive enteropathy. Treatments include topical or systemic steroids, dapsone or sulphapyridine.^{12,59}

Chronic ulcerative stomatitis

This is a new entity characterized by unique immunostaining properties.⁶⁰ It mimics oral lichen planus both clinically and histologically. Desquamative gingivitis can be its presenting feature as well. Direct immunofluorescence studies of lesional and clinically normal mucosa reveals nuclear deposits of IgG in the basal one-third of the epithelium. Circulating antinuclear antibodies are also detectable. Treatment is with potent topical steroids or hydroxychloroquine, the latter reportedly bringing about complete and long lasting remission.^{13,40,61,62}

Plasma cell gingivitis

This is an uncommon condition that presents as DG. It is generally believed to represent a hypersensitivity reaction to exogenous substances such as toothpastes, chewing gum, flavored mints, mouth washes or cinnamon flavoring products. However, in other cases no agent can be identified. Histological features of this lesion include spongiform pustules in the epithelium and a dense infiltrate of normal polyclonal plasma cells in the underlying lamina propria. Treatment consists of identification of the possible inciting agent by taking a careful clinical history (patch testing is usually negative). Removal of the offending agent results in resolution of symptoms.^{7-9,63}

CONCLUSIONS

The clinical features of dermatoses or mucocutaneous disorders where DG is a presenting manifestation have

been described. Correct identification of these conditions entails taking a careful history and performing a thorough intra-oral examination. Presence of cutaneous, nasal, ocular and genital lesions should be carefully elicited from the patient. A definitive diagnosis depends on taking an incisional biopsy from a perilesional site (with intact epithelium) and sending a fresh specimen for immunostaining. If a blistering condition is diagnosed, referral to an appropriate specialist is advised. The gingival lesions are usually treated by improved oral hygiene measures and occlusive topical corticosteroid therapy.

REFERENCES

1. Scully C, Porter SR. The clinical spectrum of desquamative gingivitis. *Semin Cutan Med Surg* 1997;16:308-313.
2. Nisengard RJ, Rogers RS. The treatment of desquamative gingival lesions. *J Periodontol* 1987;58:167-172.
3. Scully C, Laskaris G. Mucocutaneous disorders. *Periodontol* 2000 1998;18:81-94.
4. Sklavounou A, Laskaris G. Frequency of desquamative gingivitis in skin diseases. *Oral Surg Oral Med Oral Pathol* 1983;56:141-144.
5. Markopoulos AK, Antoniadis D, Papanayotou P, Trigonidis G. Desquamative gingivitis: A clinical, histopathologic, and immunologic study. *Quintessence Int* 1996;27:763-767.
6. Yih WT, Maier T, Kratochvil FJ, Zieper MB. Analysis of desquamative gingivitis using direct immunofluorescence in conjunction with histology. *J Periodontol* 1998;69:678-685.
7. Sollecito TP, Greenberg MS. Plasma cell gingivitis. Report of two cases. *Oral Surg Oral Med Oral Pathol* 1992;73:690-693.
8. Macleod RI, Ellis JE. Plasma cell gingivitis related to the use of herbal toothpaste. *Br Dent J* 1989;166:375-376.
9. Staines KS, Felix DH, Forsyth A. Desquamative gingivitis, sole manifestation of tosylamide/formaldehyde resin allergy. *Contact Dermatitis* 1998;39:90.
10. Wray D. Pyostomatitis vegetans. *Br Dent J* 1984;157:316-318.
11. Jones LE, Dolby AE. Desquamative gingivitis associated with psoriasis. *J Periodontol* 1972;43:35-37.
12. Porter SR, Scully C, Midda M, Eveson JW. Adult linear immunoglobulin A disease manifesting as desquamative gingivitis. *Oral Surg Oral Med Oral Pathol* 1990;70:450-453.
13. Church LF, Schosser RH. Chronic ulcerative stomatitis associated with stratified epithelial specific antinuclear antibodies. *Oral Surg Oral Med Oral Pathol* 1992;73:579-582.
14. Sirois DA, Fatahazadeh M, Roth R, Ertlin D. Diagnostic patterns and delays in pemphigus vulgaris: experience with 99 patients. *Arch Dermatol* 2000;136:1569-1570.
15. Rees TD. Vesiculo-ulcerative diseases and periodontal practice. *J Periodontol* 1995;66:747-748.
16. Lily JP, Spivey JD, Fotos PG. Benign mucous membrane pemphigoid with advanced periodontal involvement: Diagnosis and therapy. *J Periodontol* 1995;66:737-741.
17. Navarro CM, Sposto MR, Onofre MA, Scully C. Gingival lesions diagnosed as pemphigus vulgaris in an adolescent. Case report. *J Periodontol* 1999;70:808-812.
18. Scully C, El-Kom M. Lichen planus: review and update on pathogenesis. *J Oral Pathol* 1985;14:431-458.
19. Jandinski JJ, Shklar G. Lichen planus of the gingiva. *J Periodontol* 1976;47:724-733.
20. Robinson NA. Lichenoid tissue reactions of the oral mucosa. *Singapore Dent J* 2000;23:56-63.
21. Scully C, Beyli M, Ferreiro MC, et al. Update on oral lichen planus: aetiopathogenesis and management. *Crit Rev Oral Biol Med* 1998;9:86-122.

22. Pelisse M. The vulvo-vaginal-gingival syndrome. A new form of erosive lichen planus. *Int J Dermatol* 1989;28:381-384.
23. Eisen D. The evaluation of cutaneous, genital, scalp, nail, esophageal, and ocular involvement in patients with oral lichen planus. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1999;88:431-436.
24. Rinaggio J, Neiders ME, Aguirre A, Kumar V. Using immunofluorescence in the diagnosis of chronic ulcerative lesions of the oral mucosa. *Compend Contin Educ Dent* 1999;20:943-960.
25. Odell EW, Morgan PR. Lichenoid, psoriasiform and other types of stomatitis. In: *Biopsy pathology of the oral tissues*. London: Chapman and Hall Medical, 1998:37-51.
26. Carozzo M, Gandolfo S. The management of oral lichen planus. *Oral Dis* 1999;5:196-205.
27. Holmstrup P, Schiøtz AW, Westergaard J. Effect of dental plaque control on gingival lichen planus. *Oral Surg Oral Med Oral Pathol* 1990;69:585-590.
28. Wray D, McCord JF. Labial veneers in the management of desquamative gingivitis. *Oral Surg Oral Med Oral Pathol* 1987;64:41-42.
29. Lozada-Nur F, Miranda C. Oral lichen planus: topical and systemic therapy. *Semin Cutan Med Surg* 1997;16:295-300.
30. Rønbeck BA, Lind PO, Thrane PS. Desquamative gingivitis: Preliminary observations with tetracycline treatment. *Oral Surg Oral Med Oral Pathol* 1990;69:694-697.
31. Porter SR, Scully C, Eveson JW. The efficacy of topical cyclosporin in the management of desquamative gingivitis due to lichen planus. *Br J Dermatol* 1993;129:753-755.
32. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. *Br J Dermatol* 1999;140:338-342.
33. Weinberg MA, Insler MS, Campen RB. Mucocutaneous features of autoimmune blistering diseases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1997;84:517-534.
34. Dabelsteen E. Molecular biological aspects of acquired bullous diseases. *Crit Rev Oral Biol Med* 1998;9:162-178.
35. Scully C, Carozzo M, Gandolfo S, Puiatti P, Monteil R. Update on mucous membrane pemphigoid: a heterogeneous immune-mediated subepithelial blistering entity. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1999;88:56-68.
36. Dayan S, Simmons RK, Ahmed AR. Contemporary issues in the diagnosis of oral pemphigoid: a selective review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1999;88:424-430.
37. Williams DM. Vesiculo-bullous mucocutaneous disease: benign mucous membrane and bullous pemphigoid. *J Oral Pathol Med* 1990;19:16-23.
38. Chan LS, Ahmed AR, Anhalt GJ, et al. The first International consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. *Arch Dermatol* 2002;138:370-379.
39. Kurihara M, Nishimura F, Hashimoto T, et al. Immunopathological diagnosis of cicatricial pemphigoid with desquamative gingivitis. A case report. *J Periodontol* 2001;72:243-249.
40. Siegel MA. Intraoral biopsy technique for direct immunofluorescence studies. *Oral Surg Oral Med Oral Pathol* 1991;72:681-684.
41. Bean SF, Waisman M, Michel B, et al. Cicatricial pemphigoid: immunofluorescent studies. *Arch Dermatol* 1974;110:552-555.
42. Kelly SE, Wojnarowska F. The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. *Br J Dermatol* 1988;118:31-40.
43. Setterfield J, Shirlaw PJ, Kerr-Muir M, et al. Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease. *Br J Dermatol* 1998;138:602-610.
44. Setterfield J, Shirlaw PJ, Bhogal BS, et al. Cicatricial pemphigoid: serial titres of circulating IgG and IgA antibasement antibodies correlate with disease activity. *Br J Dermatol* 1999;140:645-650.
45. Odell EW, Morgan PR. Ulceration, acantholytic and vesiculobullous diseases. In: *Biopsy pathology of the oral tissues*. London: Chapman and Hall Medical, 1998:83-85.
46. Tauber J, Melamed S, Foster S. Glaucoma in patients with ocular cicatricial pemphigoid. *Ophthalmology* 1989;96:33-37.
47. Lamey PJ, Rees TD, Binnie WH, Rankin KV. Mucous membrane pemphigoid. Treatment experience at two institutions. *Oral Surg Oral Med Oral Pathol* 1992;74:50-53.
48. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. *Cell* 1991;67:869-877.
49. Koulu L, Kusumi A, Steinberg MS, Klaus-Kovtun V, Stanley JR. Human autoantibodies against a desmosomal core protein in pemphigus foliaceus. *J Exp Med* 1984;160:1509-1518.
50. Harman KE, Gratian MJ, Bhogal BS, et al. The use of two substrates to improve the sensitivity of indirect immunofluorescence in the diagnosis of pemphigus. *Br J Dermatol* 2000;142:1135-1139.
51. Mignogna MD, Muzio LL, Bucci E. Clinical features of gingival pemphigus vulgaris. *J Clin Periodontol* 2001;28:489-493.
52. Williams DM. Vesiculobullous mucocutaneous disease: pemphigus vulgaris. *J Oral Pathol Med* 1989;18:544-553.
53. Ishii K, Amagai M, Hall RP, et al. Characterisation of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. *J Immunol* 1997;159:2010-2017.
54. Harman KE, Seed PT, Gratian MJ, et al. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. *Br J Dermatol* 2001;144:775-780.
55. Sirois D, Leigh JE, Sollecito TP. Oral pemphigus vulgaris preceding cutaneous lesions: Recognition and diagnosis. *J Am Dent Assoc* 2000;131:1156-1160.
56. Scully C, Almeida OD, Porter SR, Gilkes JJH. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. *Br J Dermatol* 1999;140:84-89.
57. Mignogna MD, Muzio LL, Mignogna RE, Carbone R, Ruoppo E, Bucci E. Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases. *J Oral Pathol Med* 2000;29:145-152.
58. Bystryjn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. *Arch Dermatol* 1996;132:203-212.
59. Ratnam KV. IgA dermatosis in an adult Chinese population. A 10-year study of linear IgA and dermatitis herpetiformis in Singapore. *Int J Dermatol* 1988;27:21-24.
60. Jaremko WM, Beutner EH, Kumar V, et al. Chronic ulcerative stomatitis associated with a specific immunologic marker. *J Am Acad Dermatol* 1990;22:215-220.
61. Worle B, Wollenberg A, Schaller M, Kunzelmann KH, Plewig G, Meurer M. Chronic ulcerative stomatitis. *Br J Dermatol* 1997;137:262-265.
62. Lorenzana ER, Ress TD, Glass M, Detweiler JG. Chronic ulcerative stomatitis: A case report. *J Periodontol* 2000;71:104-111.
63. Odell EW, Morgan PR. Oral granulomatous conditions and other causes of diffuse mucosal swelling. In: *Biopsy pathology of the oral tissues*. London: Chapman and Hall Medical, 1998:32-33.

Address for correspondence/reprints:

Dr Robinson Narendran Andrew
 Department of Oral and Maxillofacial Surgery
 Faculty of Dentistry
 National University of Singapore
 5 Lower Kent Ridge Road
 Singapore 119074
 Singapore
 Email: rnandrew@pacific.net.sg